Description and Brand Names
药物信息提供方：IBM Micromedex
US Brand Name
- Iclusig
Descriptions
Ponatinib is used to treat chronic phase chronic myeloid leukemia (CML) in patients who have used at least 2 other treatments that did not work well. This medicine is also used to treat accelerated phase or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in patients who cannot receive any other medicine. It is also used to treat chronic phase, accelerated phase, or blast phase CML or Ph+ ALL in patients who have a specific type of abnormal gene (T315l-positive). Leukemia is a type of cancer where the body makes abnormal white blood cells.
Ponatinib is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body. Since the growth of normal cells may also be affected by ponatinib, other side effects can occur. Before you begin treatment, talk to your doctor about the benefits of this medicine as well as the possible risks of using it.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2022
版权 © 2020 IBM Watson Health。保留所有权利。信息仅供终端用户使用，不得出售、重新分发或用于其他商业目的。